Comparative Pharmacology
Head-to-head clinical analysis: INVOKAMET XR versus JANUMET XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INVOKAMET XR versus JANUMET XR.
INVOKAMET XR vs JANUMET XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of canagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, which reduces renal glucose reabsorption and lowers blood glucose, and metformin, an activator of AMP-activated protein kinase (AMPK) that decreases hepatic glucose production and improves insulin sensitivity.
JANUMET XR is a combination of sitagliptin, a DPP-4 inhibitor, and metformin, a biguanide. Sitagliptin increases active incretin levels (GLP-1, GIP), enhancing glucose-dependent insulin secretion and reducing glucagon secretion. Metformin decreases hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity.
Maximum daily dose: canagliflozin 300 mg/metformin ER 2000 mg orally once daily with the morning meal. Initial dose: canagliflozin 50 mg/metformin ER 500 mg orally twice daily or canagliflozin 150 mg/metformin ER 1000 mg orally once daily; for patients not currently on metformin, start with canagliflozin 50 mg/metformin ER 500 mg orally twice daily; for patients on metformin, switch to INVOKAMET XR based on current metformin dose.
One tablet orally once daily, with evening meal; initial dose based on patient's current sitagliptin and metformin doses, or new patients: starting dose 50 mg sitagliptin/500 mg metformin XR; maximum dose 100 mg sitagliptin/2000 mg metformin XR per day.
None Documented
None Documented
Canagliflozin: mean terminal elimination half-life is 13.1 hours (range 11-16 hours) for the 300 mg dose, consistent with once-daily dosing. Metformin: terminal elimination half-life is approximately 6.2 hours (range 4-9 hours) in patients with normal renal function; prolonged in renal impairment.
Sitagliptin: terminal half-life ~12.4 hours, allowing once-daily dosing. Metformin: terminal half-life ~6.2 hours in plasma, increased to ~17.6 hours in renal impairment.
Canagliflozin is primarily excreted as unchanged drug in urine (approximately 33%) and feces (approximately 41%), with about 7% as metabolites in urine and 34% as metabolites in feces. Metformin is excreted unchanged in urine (90-100% of absorbed dose) via tubular secretion and glomerular filtration.
Sitagliptin: ~79% excreted unchanged in urine via renal tubular secretion (active secretion) and glomerular filtration; ~13% undergoes hepatic metabolism; ~1% excreted in feces. Metformin: ~90% excreted unchanged in urine via active tubular secretion.
Category C
Category C
SGLT2 Inhibitor / Biguanide Combination
DPP-4 Inhibitor/Biguanide Combination